ATTO logo

ATTO Attovia Therapeutics, Inc.

NASDAQ · Biotechnology · Healthcare

$15.10
-0.48 (-3.08%)

A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory disease…

Market Cap: $690.26Mwww.attovia.com

Price

No data yet.

Social Signal Score

57
5d
—
30d
60
2 mentions
—
60d
57
3 mentions
—
90d
54
5 mentions
—
news: 5

Analyst Ratings

2 analysts
Buyconsensus
Strong Buy 0Buy 2Hold 0Sell 0Strong Sell 0
Avg price target$45.33+200.2%
Low $39Median $45High $52
Current Consensus

Revenue

$0.00
$0.00$330.0K$660.0K$990.0K
Mar 2025Sep 2026

Analyst Estimates

FY2026
$-4.19
$-4.49–$-4.09
2 analysts
FY2027
$-2.47
$-2.65–$-2.41
2 analysts
FY2028
$-2.84
$-3.06–$-2.56
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Tao Fu
Sector
Healthcare
Industry
Biotechnology
Employees
50
Beta
0.00
Country
US
www.attovia.com